Day 1 :
Metabolon Inc., USA
Keynote: Metabolomics: Coming of age
Time : 09:30-09:55
John Ryals received his Ph. D. in Molecular Biology from the University of Texas at Dallas in 1982. Following post doctoral work in the lab of Charles Weissmann at the Institute for Molecular Biology at the Univer sity of Zurich, Dr. Ryals joined Ciba-Geigy in the Biotechnology Research Unit at Research Triangle Park (now Syngen ta). Dr. Ryals worked in various research and management positions including Head, Agricultural Biotechnology Research, Vice- President of Biotechnology , Vice-President, Research for Novartis Cr op Protection, Inc. and Head of the Biotechnology and Genomics Center of Novartis, Inc.rnrnIn 1997, Dr. Ryals founded Paradigm Genetics, Inc., an early systems biology company, and served as the Chief Executive Officer, Chief Science Officer and President and taking the company public i n 2000. After leaving Paradigm Genetics in 2002, Dr. Ryals joined Metabolon, Inc. as Chief Executive Officer and President. For the past 10 years, Dr. Ryals research interest has been in the development of metabolomics to aid in pharmaceutical drug discovery and development, healthcare and nutrition. rnrnMetabolon, Inc. is a diagnostics and commercial services company offering the industry’s leading biochemical profiling platform. Metabolon has performed over 2000 studies to date with involving more than 500 customers and collaborators. Among these studies, Metabolon has conducted over 300 studies on cancer and in particular in contrasting various types of cancer and discovering biomarkers that can be used to differentiate various forms of the disease.rn
NextGen Metabolomics, USA
Time : 09:55-10:20
Chris Beecher was a member of the Department of Pathology , University of Michigan School of Medicine untilrn2011 when he founded NextGen Metabolomics. He was also one of the founders of Metabolon, and Metab olic Analyses.rnrnHis Ph.D. was granted in 1985 in Pharmaceutical Sciences specializing in Natural Products drug discovery. He hasrnmore than 25 years of experience in metabolomics and drug discovery and development, has published over 80 peerreviewed papers, and is listed as the inventor of 8 patents in metabolomics.
Metabolomics has the potential to both find biomarkers and to unravel complex biological processes. The discovery of Sarcosine as a biomarker for prostate cancer aggressivity, and subsequent exploration of some of its biology will be used to highlight this side of metabolomics and will also serve to underscore the bottlenecks and pitfalls to current metabolomic techniques. The IROA protocol will be examined as a way to overcome some of these bottlenecks.
National Institutes of Health, USA
Time : 10:35-11:00
Mukesh Verma is a Program Director and Chief in the Methods and Technologies Branch (MTB), Epidemiology and Genetics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute ( NCI), National Institutes of Health (NIH). Before coming to the DCCPS, he was a Program Director in the Division of Cancer Prevention (DCP), NCI, providing direction in the areas of biomarkers, early detection, risk assessment and prevent ion of cancer, and cancers associated with infectious agents. Mukesh Verma holds a M.Sc. from Pantnagar University and a Ph.D. from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University. He has published 126 research articles and reviews and edited three books in cancer epigenetics and epidemiology field.
The metabolome provides one of the most accurate reflections of cellular activity at the functional level and hence can be leveraged for discerning mechanistic information during different normal and disease states. In clinical samples metabolites are more stable than proteins or RNA. In fact, metabolomic profiling in basic, epi demiological, clinical and translational studies has revealed potential new biomarkers of disease and therapeutic outcome and led to novel mechanistic understanding of pathogenesis. These include the recent biomarkers for diabetes risk (Nat.Med.17:448-453), novel metabolites associated with cancer (Nature 462:739-44), and the discovery of over 500 unique lipids in plasma (J. Lipid Res. 51: 3299-3305) However, unlike genomics or even proteomics, the degree of metabolite complexity and heterogeneity within biological systems presents unique challenges requiring specialized skills and resources to over come. Metabolomics research efforts at NIH, especially Metabolomics Common Funds, will be discussed. The NIH Metabolomics Common Fund program is focused on enabling the comprehensive analysis of the output of biological pathways, what is considered a truer reflection of the functional status of the biological system th an other molecular “omic” approaches. The program includes multiple components focusing on the common goal of increasing metabolomics research capacity, these components include the establishment of comprehensive Resource Cores, training programs, techno logy development, reference standards and data sharing. Potential applications and issues in metabolomic approaches in cancer epidemiology will be discussed.
Lincoln Memorial University, USA
Time : 11:00-11:25
Paul L Wood has completed his Ph.D. from Queen’s University and postdoctoral studies from the NIMH. He is the director of the Metabolomics Unit at Lincoln Memorial University and is professor of pharmacology and physiology. He has published more than 280 peer-reviewed papers, serves as Editor-in-Chief of Metabolomics, and is a member of the editorial board of the JAOA.
Targeted lipidomics studies have several advantages that are superior to non-targeted studies in clinical research. First, trace metabolites are not ignored and second, absolute levels of metabolites,rnrather than rela tive levels, are reported. We will present our strategy of utilizing direct infusion ESI analyses with high resolution (140,000) mass spectrometry of a large array of targeted lipid metabolitesrnfollowed by LC-and GC-tandem mass spectrometry for further validation. In all cases, analytical standards and stable isotope internal standards are utilized. Standard cur ves with ESI, GC-MS/MS andrnLC-MS/MS all demonstrate a broad linear range. We will review the lipidomics of lymphoblasts from patients with peroxisomal disorders to demonstrate the utility of this approach.rn